Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date | Reported DateTime | Company | Symbol | Insider Relationship | Shares Traded | Average Price | Total Amount | Shares Owned | Filing |
| 2024-09-16 Purchase(A) | 2024-09-17 8:56 pm | Zenas BioPharma Inc. | ZBIO | Fairmount Funds Management LLC Fairmount Healthcare Fund II L.P. Kiselak Tomas Harwin Peter Evan Director | 300,000 | $17 | $5,100,000 | 1,929,806 (Indirect) | View |
| 2024-09-16 Purchase | 2024-09-16 8:54 pm | Zenas BioPharma Inc. | ZBIO | Fairmount Funds Management LLC Fairmount Healthcare Fund II L.P. Kiselak Tomas Harwin Peter Evan Director | 300,000 | $17 | $5,100,000 | 1,641,891 (Indirect) | View |
| 2023-09-29 Purchase | 2023-10-03 4:00 pm | Dianthus Therapeutics Inc. | DNTH | Fairmount Funds Management LLC Kiselak Tomas Harwin Peter Evan Director 10% Owner | 24,670 | $13.63 | $336,252 | 1,928,503 (Indirect) | View |
| 2023-09-26 Purchase | 2023-09-28 5:09 pm | Dianthus Therapeutics Inc. | DNTH | Fairmount Funds Management LLC Kiselak Tomas Harwin Peter Evan Director 10% Owner | 30,000 | $13.15 | $394,500 | 1,903,833 (Indirect) | View |
| 2023-09-19 Purchase | 2023-09-21 4:23 pm | Dianthus Therapeutics Inc. | DNTH | Fairmount Funds Management LLC Kiselak Tomas Harwin Peter Evan Director 10% Owner | 30,000 | $13.2 | $396,000 | 1,873,833 (Indirect) | View |
| 2023-09-12 Purchase | 2023-09-13 9:17 pm | Dianthus Therapeutics Inc. | DNTH | Fairmount Funds Management LLC Kiselak Tomas Harwin Peter Evan Director 10% Owner | 24,254 | $11.2 | $271,680 | 1,850,333 (Indirect) | View |
| 2023-07-13 Purchase | 2023-07-17 8:00 pm | Apogee Therapeutics Inc. | APGE | Fairmount Funds Management LLC Fairmount Healthcare Fund L.P. Fairmount Healthcare Fund II L.P. Fairmount Healthcare Co-Invest II L.P. Kiselak Tomas Harwin Peter Evan Director | 2,941,176 | $17 | $49,999,992 | 988,045 (Indirect Direct) | View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date | Reported DateTime | Exercisable Expiration | Company | Symnbol | Insider Relationship | Shares Traded | Conversion Price | Shares Owned | Filing |
| 2024-11-19 Exercise | 2024-11-21 6:30 pm | N/A N/A | Oruka Therapeutics Inc. | ORKA | Fairmount Funds Management LLC Fairmount Healthcare Fund II L.P. Kiselak Tomas Harwin Peter Evan Director 10% Owner | 160,160 | $0 | 3,371,922 (Indirect) | View |
| 2024-09-12 Option Award(A) | 2024-09-17 8:56 pm | N/A 2034-09-11 | Zenas BioPharma Inc. | ZBIO | Fairmount Funds Management LLC Fairmount Healthcare Fund II L.P. Kiselak Tomas Harwin Peter Evan Director | 37,000 | $0 | 1,929,806 (Indirect) | View |
| 2024-09-16 Conversion(A) | 2024-09-17 8:56 pm | N/A N/A | Zenas BioPharma Inc. | ZBIO | Fairmount Funds Management LLC Fairmount Healthcare Fund II L.P. Kiselak Tomas Harwin Peter Evan Director | 12,635,428 | $0 | 1,929,806 (Indirect) | View |
| 2024-09-12 Option Award | 2024-09-16 8:54 pm | N/A 2034-09-11 | Zenas BioPharma Inc. | ZBIO | Fairmount Funds Management LLC Fairmount Healthcare Fund II L.P. Kiselak Tomas Harwin Peter Evan Director | 37,000 | $0 | 1,641,891 (Indirect) | View |
| 2024-09-16 Conversion | 2024-09-16 8:54 pm | N/A N/A | Zenas BioPharma Inc. | ZBIO | Fairmount Funds Management LLC Fairmount Healthcare Fund II L.P. Kiselak Tomas Harwin Peter Evan Director | 12,635,428 | $0 | 1,641,891 (Indirect) | View |
| 2024-09-11 Option Award | 2024-09-13 4:55 pm | N/A N/A | Oruka Therapeutics Inc. | ORKA | Fairmount Funds Management LLC Fairmount Healthcare Fund II L.P. Kiselak Tomas Harwin Peter Evan Director 10% Owner | 275,000 | $23 | 3,212,082 (Indirect) | View |
| 2024-09-11 Option Award | 2024-09-13 4:55 pm | N/A N/A | Oruka Therapeutics Inc. | ORKA | Fairmount Funds Management LLC Fairmount Healthcare Fund II L.P. Kiselak Tomas Harwin Peter Evan Director 10% Owner | 160 | $23,000 | 3,212,082 (Indirect) | View |
Ownership | 2024-09-12 9:41 pm | N/A N/A | Zenas BioPharma Inc. | ZBIO | Fairmount Funds Management LLC Fairmount Healthcare Fund II L.P. Kiselak Tomas Harwin Peter Evan Director 10% Owner | 0 | $0 | 1,592,806 (Indirect) | View |
Ownership | 2024-09-06 5:07 pm | N/A N/A | Oruka Therapeutics Inc. | ORKA | Fairmount Funds Management LLC Fairmount Healthcare Fund II L.P. Fairmount Healthcare Co-Invest III L.P. Kiselak Tomas Harwin Peter Evan Director 10% Owner | 0 | $0 | 19,662,752 (Indirect) | View |
| 2024-06-26 Option Award | 2024-06-28 4:05 pm | N/A 2034-06-26 | Viridian Therapeutics Inc. | VRDN | Harwin Peter Evan Director | 21,000 | $0 | 21,000 (Indirect) | View |
| 2024-06-05 Option Award | 2024-06-13 7:11 pm | N/A 2034-06-05 | Cogent Biosciences Inc. | COGT | Harwin Peter Evan Director | 44,700 | $0 | 44,700 (Direct) | View |
| 2024-06-05 Option Award | 2024-06-07 8:00 pm | N/A 2034-06-05 | Apogee Therapeutics Inc. | APGE | Fairmount Funds Management LLC Kiselak Tomas Harwin Peter Evan Director | 20,740 | $0 | 20,740 (Direct) | View |
| 2024-05-14 Option Award | 2024-05-16 4:10 pm | N/A 2034-05-14 | Spyre Therapeutics Inc. | SYRE | Fairmount Funds Management LLC Kiselak Tomas Harwin Peter Evan Director | 22,646 | $0 | 22,646 (Indirect) | View |
| 2024-04-25 Exercise | 2024-04-25 4:55 pm | N/A N/A | Spyre Therapeutics Inc. | SYRE | Fairmount Funds Management LLC Fairmount Healthcare Fund II L.P. Kiselak Tomas Harwin Peter Evan Director | 3,730,672 | $0 | 5,176,222 (Indirect) | View |
| 2024-03-28 Other | 2024-04-01 5:44 pm | N/A N/A | Apogee Therapeutics Inc. | APGE | Fairmount Funds Management LLC Fairmount Healthcare Fund L.P. Fairmount Healthcare Fund II L.P. Kiselak Tomas Harwin Peter Evan Director | 498,765 | $0 | 9,006,126 (Indirect) | View |
| 2024-01-29 Other | 2024-01-31 4:31 pm | N/A N/A | Apogee Therapeutics Inc. | APGE | Fairmount Funds Management LLC Fairmount Healthcare Fund L.P. Fairmount Healthcare Fund II L.P. Fairmount Healthcare Co-Invest II L.P. Kiselak Tomas Harwin Peter Evan Director | 943,695 | $0 | 1,046,027 (Indirect) | View |
| 2024-01-22 Option Award | 2024-01-24 7:02 pm | N/A N/A | Dianthus Therapeutics Inc. | DNTH | Fairmount Funds Management LLC Kiselak Tomas Harwin Peter Evan Director 10% Owner | 834,334 | $12 | 3,595,170 (Indirect) | View |
| 2024-01-22 Option Award | 2024-01-24 7:02 pm | N/A N/A | Dianthus Therapeutics Inc. | DNTH | Fairmount Funds Management LLC Kiselak Tomas Harwin Peter Evan Director 10% Owner | 832,333 | $12 | 3,595,170 (Indirect) | View |
| 2023-12-29 Other | 2023-12-29 5:00 pm | N/A N/A | Spyre Therapeutics Inc. | SYRE | Fairmount Funds Management LLC Fairmount Healthcare Fund L.P. Fairmount Healthcare Fund II L.P. Fairmount Healthcare Co-Invest L.P. Kiselak Tomas Harwin Peter Evan Director 10% Owner | 3,841,518 | $0 | 5,485,719 (Indirect) | View |
| 2023-12-07 Option Award | 2023-12-11 5:41 pm | N/A N/A | Spyre Therapeutics Inc. | SYRE | Fairmount Funds Management LLC Fairmount Healthcare Fund L.P. Fairmount Healthcare Fund II L.P. Fairmount Healthcare Co-Invest L.P. Kiselak Tomas Harwin Peter Evan Director 10% Owner | 16,667 | $600 | 16,667 (Indirect) | View |
| 2023-11-24 Conversion | 2023-11-28 4:05 pm | N/A N/A | Spyre Therapeutics Inc. | AGLE | Fairmount Funds Management LLC Fairmount Healthcare Fund L.P. Fairmount Healthcare Fund II L.P. Fairmount Healthcare Co-Invest L.P. Kiselak Tomas Harwin Peter Evan Director 10% Owner | 3,521,367 | $0 | 4,250,938 (Indirect) | View |
| 2023-09-11 Option Award | 2023-09-13 9:17 pm | N/A 2033-09-10 | Dianthus Therapeutics Inc. | DNTH | Fairmount Funds Management LLC Kiselak Tomas Harwin Peter Evan Director 10% Owner | 6,500 | $0 | 1,850,333 (Indirect) | View |
Ownership | 2023-09-13 8:55 pm | N/A N/A | Dianthus Therapeutics Inc. | DNTH | Fairmount Funds Management LLC Kiselak Tomas Harwin Peter Evan Director 10% Owner | 0 | $0 | 1,819,579 (Indirect) | View |
| 2023-07-13 Option Award | 2023-07-17 8:00 pm | N/A 2033-07-13 | Apogee Therapeutics Inc. | APGE | Fairmount Funds Management LLC Fairmount Healthcare Fund L.P. Fairmount Healthcare Fund II L.P. Fairmount Healthcare Co-Invest II L.P. Kiselak Tomas Harwin Peter Evan Director | 95,516 | $0 | 988,045 (Direct) | View |
Ownership | 2023-06-30 5:32 pm | N/A N/A | Aeglea BioTherapeutics Inc. | AGLE | Fairmount Funds Management LLC Fairmount Healthcare Fund L.P. Fairmount Healthcare Fund II L.P. Fairmount Healthcare Co-Invest L.P. Kiselak Tomas Harwin Peter Evan Director 10% Owner | 0 | $0 | 536,284,540 (Indirect) | View |
| 2023-06-14 Option Award | 2023-06-16 8:00 pm | N/A 2023-06-14 | Viridian Therapeutics Inc. | VRDN | Harwin Peter Evan Director | 20,000 | $0 | 20,000 (Indirect) | View |
| 2023-06-07 Option Award | 2023-06-08 4:37 pm | N/A 2033-06-07 | Cogent Biosciences Inc. | COGT | Harwin Peter Evan Director | 36,700 | $0 | 36,700 (Direct) | View |
| 2022-06-08 Option Award | 2022-06-10 07:30 am | N/A 2032-06-08 | Viridian Therapeutics Inc. | VRDN | Harwin Peter Evan Director | 12,500 | $0 | 12,500 (Indirect) | View |
| 2022-06-07 Option Award | 2022-06-09 5:08 pm | N/A 2032-06-07 | Cogent Biosciences Inc. | COGT | Harwin Peter Evan Director | 30,700 | $0 | 30,700 (Direct) | View |
| 2021-06-03 Option Award | 2021-06-16 6:26 pm | N/A 2031-06-03 | Viridian Therapeutics Inc. | VRDN | Harwin Peter Evan Director | 12,500 | $0 | 12,500 (Direct) | View |
| 2021-03-11 Option Award | 2021-03-15 8:44 pm | N/A 2031-03-11 | Cogent Biosciences Inc. | COGT | Harwin Peter Evan Director | 60,000 | $0 | 60,000 (Direct) | View |
| 2021-02-04 Option Award | 2021-02-08 5:40 pm | N/A 2031-02-04 | Viridian Therapeutics Inc. | VRDN | Harwin Peter Evan Director | 25,000 | $0 | 25,000 (Direct) | View |
| 2020-10-27 Option Award | 2020-10-29 5:19 pm | N/A 2030-10-26 | MIRAGEN THERAPEUTICS INC. | MGEN | Harwin Peter Evan Director | 24,000 | $0 | 24,000 (Direct) | View |
| 2020-08-27 Option Award | 2020-08-31 1:08 pm | N/A 2030-08-27 | Unum Therapeutics Inc. | UMRX | Harwin Peter Evan Director | 28,661 | $0 | 28,661 (Direct) | View |